MCE
Adagrasib
Adagrasib
Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction.
Couldn't load pickup availability
General Specifications
1) Purity: 99.93%2) Molecular Weight: 604.12
3) Formula: C32H35ClFN7O2
4) CAS No.: 2326521-71-3
5) Appearance: Solid
6) Color: White to yellow
7) SMILE: N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C(CN(C4=C5C(Cl)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1
8) Shipping: Room temperature in continental US; may vary elsewhere.
9) Storage: Powder: -20°C, 3 years ; 4°C, 2 years ; In solvent: -80°C, 6 months ; -20°C, 1 month
Safety & Documentation
Error in entry: 1) Datasheet, https://cdn.shopify.com/s/files/1/0716/2553/9802/files/Datasheet_HY-130149.pdf?v=1734506157 , 2) MSDS, https://cdn.shopify.com/s/files/1/0716/2553/9802/files/MSDS_HY-130149.pdf?v=1734506830 , 3) Handling Instruction, https://cdn.shopify.com/s/files/1/0716/2553/9802/files/Handling_Instructions_HY-130149.pdf?v=1734506812
{# This line will help debug any improperly formatted entries #}Disclaimer: Products are chemical reagents for research use
only and are not intended for human use. We do not sell to patients.
